Morningstar

Novo Nordisk Launches Discounted Subscription Program for Wegovy Obesity Drugs

Provided by Dow Jones

By Dominic Chopping 




  Novo Nordisk has launched a new discounted subscription program for its Wegovy obesity drugs in the U.S. as it tries to win customers by offering a "lower, predictable monthly price." 



  The Danish drugmaker said Tuesday that eligible patients who pay for the drugs themselves can opt for a 3-, 6- or 12-month subscription for the Wegovy shot and the two highest doses of the recently launched pill version of its blockbuster weight-loss treatment. 



  The company said the new plans allow patients to save up to $600 a year on the pill and up to $1,200 a year on the injection. 



  As of Tuesday, patients can access the program through Ro, WeightWatchers and LifeMD, with Hims & Hers, Sesame, and other telehealth providers coming online soon. 



  "The program is designed to reduce cost uncertainty and help people start and stay on [the] FDA-approved obesity treatment," Novo Nordisk said in a statement. 





  Write to Dominic Chopping at dominic.chopping@wsj.com 





  (END) Dow Jones Newswires



  March 31, 2026 08:37 ET (12:37 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
The 10 Best Companies to Invest in Now
 
The stocks of these high-quality companies look cheap today. 
 
 
Tori Brovet 
 
 
 
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
 
Russ Kinnel shares investment ideas from his annual Thrilling Funds list and discusses how he screens for quality investments in a sea of options. 
 
 
Russel Kinnel and Ivanna Hampton 
 
 
 
4 Stocks to Buy Before They Rise Further
 
Plus, the member of the triple-digit club reporting earnings this week. 
 
 
David Sekera, CFA and Susan Dziubinski 
 
 
 
The Top Funds for a Simpler Retirement Portfolio
 
For retirement savers and retirees, Christine Benz highlights all-in-one funds and core funds that can serve as building blocks for a streamlined portfolio. 
 
 
Christine Benz 
 
 
 
The 10 Best Dividend Stocks
 
These are the top dividend-paying stocks to buy today. 
 
 
Susan Dziubinski 
 
 
 
 

			Sponsor Center